Allenex AB's average Accounts Receivable for the
three
months ended in Mar. 2016 was £1.00 Mil. Allenex AB's Revenue for the
three
months ended in Mar. 2016 was £2.75 Mil.
Hence, Allenex AB's Days Sales Outstanding for the
three
months ended in Mar. 2016 was 33.34.
The historical rank and industry rank for Allenex AB's Days Sales Outstanding or its related term are showing as below:
LTS:0O9J'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 27.03 Med: 34.42 Max: 281.52
Current: 34.88
During the past 11 years, Allenex AB's highest Days Sales Outstanding was 281.52. The lowest was 27.03. And the median was 34.42.
LTS:0O9J's Days Sales Outstanding is not ranked
in the Biotechnology industry.
Industry Median: 72.245
vs LTS:0O9J: 34.88
Allenex AB's Days Sales Outstanding
declined
from Mar. 2015 (34.02) to Mar. 2016 (33.34).
Allenex AB Days Sales Outstanding Historical Data
The historical data trend for Allenex AB's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Allenex AB's Days Sales Outstanding
For the Biotechnology subindustry, Allenex AB's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Allenex AB's Days Sales Outstanding Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Allenex AB's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Allenex AB's Days Sales Outstanding falls into.
Allenex AB Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Allenex AB (LTS:0O9J) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Allenex AB Days Sales Outstanding Related Terms
Thank you for viewing the detailed overview of Allenex AB's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.
Allenex AB creates life-science companies in collaboration with innovators. The process requires identifying ideas with commercial potential, and then contributing entrepreneurship and capital. Its portfolio consists of twelve companies, four in drug development and biotechnology, and eight in diagnostics and medical technologies. The company portfolio accounts for more than 50 different projects, some nearing the commercialization phase while others are already selling their products of services, in a wide range of therapeutic areas- from HIV and cancer to eye disease and allergies. Its Drug Development and Biotechnology business area is comprised of four companies: Anamar Medical, IMED, Novahep, and Recopharma. Anamar Medical develops drugs and biomarkers for diagnosing and monitoring/predicting chronic joint diseases such as rheumatoid arthritis and osteoarthritis, with five drug candidates' two biomarkets, and two commercial biomarkers. IMED develops human monoclonal antibodies (MAB) that induce or block natural cell death or apoptosis, and intending to develop antibodies for major therapeutic areas, including HIV, cancer, and transplantation. Novahep, in collaboration with the Karolinska Institute, aims to differentiate cell lines of fetal liver stem cells, which can then be used in the transplantation sector. Recopharma develops mucins for the vaccine market and antimicrobial substances to combat bacteria and viruses that may cause eye infection, influenza, and the Norwalk virus. The companies in the Diagnostics and Medical Technology business area include Absorber, Bioresonator, Biovator, Likvor, Olerup, Olerup SSP, Oncolog, Ortoviva, and Pharmacolog. These companies develop products such as the XM-ONE transplantation test, biomedical sensors, allergic reaction testing technology for the pharmaceutical, cosmetic and chemical industries, a diagnostic instrument to measure cerebrospinal fluid pressure (CSF), tools to facilitate the insertion of artificial discs in spinal surgery, and systems to control the content and concentration of liquid pharmaceutical drugs.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LTS:0O9J has been successfully added to your 